

Total nodule number is an independent prognostic factor in resected stage III non-small cell lung cancer: a deep learning powered study

1 **Xiuyuan Chen^{1¶}, Qingyi Qi^{2¶}, Zewen Sun^{1¶}, Dawei Wang³, Jinlong Sun³, Weixiong Tan³,**
2 **Xianping Liu¹, Taorui Liu¹, Nan Hong^{2*}, Fan Yang^{1*}**

3 [¶]These authors contributed equally to this work and share first authorship

4 ¹ Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China

5 ² Department of Radiology, Peking University People's Hospital, Beijing, China

6 ³ Institute of Advanced Research, Beijing Infervision Technology Co., Ltd., Beijing, China

7 *** Correspondence:**

8 Nan Hong, hongnan@bjmu.edu.cn

9 Fan Yang, yangfan@pku.edu.cn

10 **Keywords: nodule number, non-small cell lung cancer, prognosis, artificial intelligence,**
11 **multiple pulmonary nodules**

12 **Abbreviations list:** AI, artificial intelligence; CAD, computer aided detection/diagnosis; CNN,
13 convolutional neural network; GGN, ground-glass nodule; HR, hazard ratio; IPM, intrapulmonary
14 metastasis; LDCT, low-dose computed tomography; MPLC, multiple primary lung cancer;
15 NSCLC, non-small cell lung cancer; OS, overall survival; PET, positron emission tomography;
16 PN, pulmonary nodule; RFS, recurrence-free survival; TNN, total nodule number.

17

18 ABSTRACT

19 Almost every lung cancer patient has multiple pulmonary nodules while the significance of
20 nodule multiplicity in locally advanced non-small cell lung cancer (NSCLC) remained unclear.
21 This study explores the relationship between deep learning detected total nodule number (TNN)
22 and survival outcomes in patients with surgical resected stage I-III NSCLC. Patients who
23 underwent surgical resection for stage I-III NSCLC with accessible preoperative chest CT scan
24 from 2005 to 2018 were identified from our database. Deep learning-based AI algorithms using
25 convolutional neural networks (CNN) was applied for pulmonary nodule (PN) detection and
26 classification. Of the 2126 patients, a total number of 33410 PNs were detected by AI. Median
27 TNN detected per person was 12 (IQR 7-20). AI-detected TNN (analyzed as continuous variable)
28 was independent prognostic factor for both RFS (HR 1.012, 95% CI 1.002-1.022, $p = 0.021$) and
29 OS (HR 1.013, 95% CI 1.002-1.025, $p = 0.021$) in multivariate analyses of stage III cohort; while
30 it was not significantly associated with survival in stage I and II cohorts. In terms of nodule
31 categories, the numbers of upper-lobe nodule, same-side nodule, other-side nodule, solid nodule,
32 and even solid nodule at small size ($\leq 6\text{mm}$) were independent prognostic factors; while the
33 numbers of middle/lower-lobe nodule, same-lobe nodule, subsolid nodule, calcific nodule and
34 perifissural nodule were not associated with survival. In survival tree analysis, rather than using
35 traditional IIIA and IIIB classification, the model grouped cases by AI-detected TNN (lower vs.
36 higher: log-rank $p < 0.001$), which showed superior discrimination of survival in stage III cohort.
37 In conclusion, AI-detected TNN was significantly associated with survival in patients with
38 surgical resected stage III NSCLC. Lower TNN detected on preoperative CT scan indicated better
39 prognosis in patients who underwent complete surgical resection.

40 INTRODUCTION

41 Lung cancer is a leading cause of cancer-related death worldwide [1]. Since early detection of
42 cancer is an important opportunity for decreasing mortality, multiple randomized trials and
43 guidelines recommend lung cancer screening using low-dose CT (LDCT) for high-risk
44 individuals [2-7]. With the adoption of LDCT for lung cancer screening, the number of chest CT
45 scans increase dramatically each year [8]. To address the repetitive and burdensome work of
46 dealing with mostly normal images, computer aided detection/diagnosis (CAD), which has a
47 computer to perform a given task consistently and tirelessly, becomes extremely appealing [9].

48 CAD supported by machine-learning techniques has been utilized to detect PN since 2002 [10].
49 Although standardized CAD systems have been proven to improve diagnostic accuracy, few of
50 them have been implemented in actual clinical practice due to its high dependence on imaging
51 processing and false positive rates [11, 12]. In recent years, deep-learning based AI algorithms
52 using convolutional neural networks (CNN) have attracted considerable attention in the area of
53 machine-learning. The key advantage that CNNs have over conventional CAD techniques is their
54 ability to self-learn previously unknown features, maximizing classification with limited direct
55 supervision [13]. Thus, CNNs bring about a significant false-positive reduction in PN detection,
56 recognition, segmentation, and classification [14-19].

57 The key issue in the management of incidental PNs detected on CT images is to differentiate
58 benign and malignant nodules. Radiological features, such as larger nodule size, upper lobe
59 location, marginal spiculation, and faster growth rate are generally considered as risk factors for

60 malignancy [20-25]. These principles mainly focus on the assessment of the largest or most
61 suspicious nodule. However, half of the patients detected with PNs have multiple nodules [26].
62 Nodule multiplicity, which is a potential indicator for malignancy, is commonly overlooked. Only
63 limited data concerning the relationship between TNN and lung cancer probability is available. In
64 the PanCan and BCCA trials, lower TNN was associated with an increased risk of lung cancer
65 [20]. While another study analyzing patients from the NELSON trial showed that the risk of lung
66 cancer increased as TNN rising from 1 to 4, but decreased in patients with 5 or more nodules [26].

67 The results of above-mentioned screening trials indicated that TNN was either negatively or not
68 significantly associated with lung cancer probability, which might reflect a low incidence of
69 multiple malignancies in screening population [27]. However, for patients with high pretest
70 probability of malignancy, whether TNN plays a role in determining lung cancers probability with
71 multiple pulmonary sites of involvement, distinguishing multiple primary lung cancers (MPLC)
72 from intrapulmonary metastasis (IPM), and thus, predicting prognosis remains unknown. The
73 purpose of this study was to calculate TNN detected on preoperative CT images using CNN-based
74 AI algorithm, and explore in-depth the relationship between AI-detected TNN and survival
75 outcomes in patients with resectable stage I-III NSCLC.

76 **MATERIALS AND METHODS**

77 **Patients**

78 We retrospectively reviewed the medical records of patients pathologically diagnosed with
79 stage I-III (according to the 8th edition of American Joint Committee on Cancer [AJCC]
80 prognostic group) NSCLC who underwent surgical resection at the department of thoracic surgery
81 of Peking University People's Hospital from October 2005 to December 2018. Only patients
82 received preoperative chest CT scan within 90 days prior to the surgery in our institution were
83 included. Patients were excluded: 1) if they received neoadjuvant therapy; 2) if the surgical
84 margin was positive; 3) if perioperative death occurred within 30 days; 4) if the follow-up
85 information was inadequate.

86 **AI-Powered PN Detection**

87 InferReadTM CT Lung, a widely used deep learning-based AI algorithm developed by
88 InferVision, was applied for PN detection in this study. Only the last chest CT scan before surgery
89 was chosen. Firstly, PNs was detected by AI algorithm and TNN was calculated accordingly. Then,
90 PNs were classified according to their lobar distributions (left lower lobe, left upper lobe, right
91 lower lobe, right middle lobe, and right upper lobe), locations (same lobe as the primary tumor
92 [same-lobe], ipsilateral lobe different from the primary tumor [same-side], and contralateral lobe
93 [other-side]), and types (solid nodule, mixed ground-glass nodule [m-GGN], pure ground-glass
94 nodule [p-GGN], calcific nodule, and perifissural nodule). Moreover, solid and subsolid (m-GGN
95 and p-GGN) nodules were further categorized based on their size.

96 **Statistical Analysis**

97 Continuous variables were presented as median with interquartile range (IQR) and were
98 analyzed by using Wilcoxon rank-sum test and one-way analysis of variance (ANOVA).
99 Categorical variables were presented as frequencies and percentages. Survival curves were

100 compared using Kaplan-Meier method with log-rank test. Univariate Cox proportional hazards
101 models were built first to determine which factors were significantly associated with survival.
102 Then, multivariate Cox models were constructed incorporating factors with $p \leq 0.10$ identified in
103 the univariate analyses.

104 In stage III cohort, maximally selected log-rank statistics were used to determine the optimal
105 cutoff value of nodule number for predicting OS. Patients were then dichotomized into lower- and
106 higher-nodule number groups according to the estimated cut-point. Furthermore, least absolute
107 shrinkage and selection operator (LASSO) Cox regression model with cross-validation was
108 utilized to select the most useful prognostic features among all categories of AI-detected nodule
109 numbers.

110 Finally, survival tree analysis was conducted to generate a tree-based model for survival data
111 using log-rank test statistics for recursive partitioning. This tree-based model grouped cases
112 according to the best split of OS using AI-detected TNN and the 8th edition of AJCC prognostic
113 group. A candidate grouping scheme was then developed based on this tree analysis.

114 All the statistical analyses were executed using R version 4.0.0 for Windows (R Foundation for
115 Statistical Computing, Vienna, Austria). All the statistical tests were two-sided and p values of
116 0.05 or less were considered statistically significant.

117 **Ethics**

118 The study involving human participants were reviewed and approved by the Institutional
119 Review Board of Peking University People's Hospital (2020PHB385-01). Since only
120 de-identified data were used in this study, informed consents for participants were waived by the
121 committee.

122 **RESULTS**

123 **Characteristics of Patients and Nodules**

124 A total of 2126 patients who underwent surgical resection for stage I-III NSCLC with
125 accessible preoperative chest CT scan were included in this study. The median follow-up time
126 was 33 months (IQR 21-48). The demographic and clinicopathologic characteristics of the
127 patients are summarized in Table 1.

128 The framework of deep-learning powered PN detection algorithm and an example of 3D
129 reconstruction of AI-detected nodules are shown in Figure 1A and B. Of the 2126 patients, a total
130 number of 33410 PNs were detected. The features of these AI-detected nodules are given in Table
131 2. The distributions of AI-detected TNN, solid nodule number, and subsolid nodule number per
132 person were all positively skewed, and the medians of these three above-mentioned nodules were
133 12 (IQR 7-20), 6 (IQR 3-10), and 3 (IQR 1-6) respectively (Figure 2A to C).

134 When considering the discrepancy of nodule number among different stages, we found that
135 there was no statistically significant difference between means of TNN (one-way ANOVA $p =$
136 0.655). However, means of solid nodules were significantly higher in patients with stage II and III
137 disease, while means of subsolid ones were higher in those with stage I disease (both $p < 0.001$,
138 Figure 2D to F). Moreover, patients with late-stage disease tended to have more solid nodules

139 with greater size (Supplementary Figure 1).

140 **Survival Analyses**

141 We analyzed the survival of the patients by stage according to the 8th edition of AJCC
142 prognostic group (Figure 3A and B). The differences of both RFS and OS between any two stages
143 were statistically significant (pairwise comparison $p < 0.001$). Cox proportional hazards models
144 were then built to determine the prognostic factors of the entire cohort (Supplementary Table). In
145 univariate analysis, lower AI-detected TNN (as continuous variable) was associated with
146 improved RFS (HR 1.008, 95% CI 1.001-1.014, $p = 0.017$), while it was not significantly
147 associated with improved OS (HR 1.006, 95% CI 0.999-1.012, $p = 0.099$). In multivariate
148 analysis, TNN was neither an independent prognostic factor for RFS (HR 1.006, 95% CI
149 0.999-1.012, $p = 0.080$) nor for OS (HR 1.002, 95% CI 0.995-1.009, $p = 0.590$) after adjusting for
150 age, sex, smoking history, surgical approach, surgical procedure, histologic type, adjuvant therapy
151 status, and pathologic T and N stage.

152 Subgroup analysis stratified by stage was then performed to assess whether AI-detected TNN
153 was an independent prognostic factor for patients in each stage. We found that TNN was not
154 significantly associated with survival for patients with stage I (RFS: HR 1.010, 95% CI
155 0.998-1.022, $p = 0.102$; OS: HR 1.003, 95% CI 0.989-1.017, $p = 0.689$) and stage II disease (RFS:
156 HR 1.000, 95% CI 0.988-1.013, $p = 0.973$; OS: HR 1.000, 95% CI 0.989-1.012, $p = 0.965$).
157 However, in stage III cohort, fewer TNN was independently associated with improved survival in
158 multivariate analyses (RFS: HR 1.012, 95% CI 1.002-1.022, $p = 0.021$; OS: HR 1.013, 95% CI
159 1.002-1.025, $p = 0.021$) (Table 3 and Table 4).

160 **Exploratory Analyses in Stage III Cohort**

161 To further evaluate the prognostic effect of AI-detected TNN, we used maximally selected
162 log-rank statistics to dichotomize patients into lower- and higher-TNN groups. The optimal cutoff
163 value of 8 was selected (Supplementary Figure 2). When compared with patients with higher
164 TNN (> 8), those with lower TNN (≤ 8) had significantly improved OS (log-rank $p < 0.001$,
165 Figure 4A). Lower TNN was also an independent favorable predictor for OS in multivariate
166 analysis (HR 2.348, 95% CI 1.351-4.082, $p = 0.002$).

167 To assess which of the components were associated with survival, we classified AI-detected
168 nodules into different categories. When analyzed as continuous variables, the numbers of
169 upper-lobe nodule (HR 1.028, 95% CI 1.008-1.049, $p = 0.006$), same-side nodule (HR 1.032, 95%
170 CI 1.001-1.064, $p = 0.046$), other-side nodule (HR 1.020, 95% CI 1.001-1.039, $p = 0.040$), solid
171 nodule (HR 1.020, 95% CI 1.004-1.036, $p = 0.012$), and even solid nodule at small size (≤ 6 mm)
172 (HR 1.027, 95% CI 1.007-1.047, $p = 0.008$) were independently associated with OS in
173 multivariate analyses; however, none of the numbers of middle/lower-lobe nodule (HR 1.016, 95%
174 CI 0.994-1.039, $p = 0.153$), same-lobe nodule (HR 1.021, 95% CI 0.986-1.056, $p = 0.246$),
175 m-GGN (HR 1.104, 95% CI 0.885-1.376, $p = 0.381$), p-GGN (HR 1.015, 95% CI 0.976-1.056, p
176 $= 0.462$), calcific nodule (HR 1.021, 95% CI 0.975-1.068, $p = 0.384$), and periferissural nodule (HR
177 1.007, 95% CI 0.792-1.279, $p = 0.957$) were significantly associated with survival.

178 The five above-mentioned nodule numbers, which were independent prognostic factors for OS
179 as continuous variables, were set as binary variables according to their optimal cutoff values.

180 Similarly, compared with patients with higher nodule numbers, those with lower nodule numbers
181 had significantly improved OS (Figure 4B to F). In addition, the numbers of upper-lobe nodule
182 (HR 2.532, 95% CI 1.567-4.091, $p < 0.001$), other-side nodule (HR 1.957, 95% CI 1.322-2.898, p
183 < 0.001), solid nodule (HR 1.851, 95% CI 1.241-2.761, $p = 0.003$), and solid nodule at small size
184 ($\leq 6\text{mm}$) (HR 1.862, 95% CI 1.248-2.779, $p = 0.002$) were still independent prognostic factors for
185 OS in multivariate analyses.

186 Finally, to evaluate which of the components contributed most to prognosis, LASSO Cox
187 regression model incorporating both clinicopathologic features and all categories of AI-detected
188 nodule numbers (as continuous variables) was built (Supplementary Figure 3). Seven features
189 with nonzero coefficient were as follows: age (0.021), smoking history (0.106), surgical approach
190 (0.669), adjuvant therapy status (-0.389), IIIA/IIIB classification (0.095), upper-lobe nodule
191 number (0.014), and small ($\leq 6\text{mm}$) solid nodule number (0.008). Thus, the number of upper-lobe
192 nodule, followed by solid nodule at small size, were individual features that contributed most to
193 the model and correlated best with OS among all categories of AI-detected nodule numbers.

194 **Survival Tree Analyses**

195 A tree-based model incorporating AI-detected TNN and the 8th edition of AJCC prognostic
196 group was constructed based on the best split of OS in the entire cohort (Figure 5A). We found
197 that discrimination of survival curves of sub-stages was unsatisfactory with the current staging
198 system in our study, especially in sub-stages of IA2 to IB (IA2 vs. IA3: log-rank $p = 0.177$; IA3
199 vs. IB: log-rank $p = 0.778$) and IIA to IIB (log-rank $p = 0.236$). Moreover, in stage III cohort,
200 rather than using the traditional IIIA and IIIB classification, the model grouped OS by AI-detected
201 TNN (lower vs. higher: log-rank $p < 0.001$), since it showed superior discrimination of survival.
202 Accordingly, Kaplan-Meier curves of OS by the tree-based grouping scheme were shown in
203 Figure 5B.

204 **Treatment Failure Analyses**

205 To evaluate the potential relationship between AI-detected TNN and the tumor recurrence
206 pattern, we further divided stage III cohort into two groups according to the first disease
207 progression site. Among all 263 patients, 60 had local recurrent disease, 40 had distant metastatic
208 disease, and 19 had progressive disease without specified pattern. Compared with distant
209 metastasis group (median: 17 [IQR 10.75-23.25]), patients with local recurrent disease had lower
210 AI-detected TNN (median: 14 [IQR 7.75-18.25]). However, the difference between these two
211 groups was not statistically significant (Wilcoxon rank-sum $p = 0.077$, Supplementary Figure 4).

212 **DISCUSSION**

213 The widespread application of artificial intelligence algorithm in PN detection is reshaping our
214 knowledge on this topic. The number of patients with tens or even hundreds of PNs is rapidly
215 growing, while the interpretation of these lesions and its impact on surgical decision making are
216 complicated and yet underrepresented. As the number of nodules grows, accurate diagnosis for
217 every single nodule becomes labor-intensive and statistically challenging. As an alternative, we
218 hypothesized that TNN measured by deep-learning algorithm may serve as a surrogate indicator
219 of the probability of malignancy and metastasis in locally advanced NSCLC. Such hypothesis is
220 proved preliminarily by our result that TNN is an independent prognostic factor in stage III lung

221 cancer.

222 The accurate measurement of TNN is highly challenging. First, the definition of PN varies
223 across radiologists and surgeons due to their different purposes: some may only report guideline
224 mandated PNs in order not to provoke panic of patients, while others may report as many as one
225 can detect for more accurate surgery planning. Unfortunately, both standards are rather subjective
226 and less repeatable. Second, the accuracy and robustness of a single radiologist or surgeon is
227 limited. The sensitivity of PN detection by a single radiologist is around 77% and can be
228 increased to 90% with a concurrent radiologist's help [28]. However, such method is
229 time-consuming and still subjected to human error.

230 The emerging of deep learning-based AI algorithm ensured the objectiveness and robustness of
231 PN detection and thus the measurement of TNN. Mature algorithms have reached a diagnosis
232 sensitivity of 85-100% [29-31]. The best-performing deep learning algorithm in LUNA16
233 challenge, which based on the LIDC-IDRI dataset, exhibited an excellent sensitivity of over 95%
234 at fewer than 1.0 false positives per scan [32]. The algorithm (InferReadTM CT Lung, InferVision)
235 in this study is trained using over 350 thousand chest CTs labeled by radiologists [33]. In
236 real-world, the performance of this model has reached AUC at 0.89 in PN detection and can
237 significantly improve the performance assisting radiologists [33-35]. Our result showed median
238 TNN at 12 per patient, much higher than the median of 2 per patient reported in the malignant
239 cohort of NELSON study [26]. Such difference may, on one hand, because of the difference in CT
240 radiation dosage, while on the other hand, reflect the difference in diagnosis preference and
241 consistency between AI and human radiologists.

242 From the clinical aspect, our results suggested that TNN may be a visualized representation of
243 tumor burden in stage III NSCLC patients. Different from the result of NELSON study that shows
244 higher nodule count is in favor of benign diagnosis [26], our study focused on more advanced
245 NSCLC patients instead of high-risk screening population. Past evidences vaguely showed that,
246 with confirmed histology, extensive nodal or systemic metastasis are relative arguments for
247 multiple PNs to be IPM [36], suggesting that high TNN may relate to higher pretest probability of
248 IPM. Our result further supported this speculation by revealing the survival advantage of lower
249 TNN group comparing to higher TNN. Such advantage existed when analyzing TNN as either a
250 continuous variable or a binary variable, which strengthened the argument.

251 It is worth notice that the major impact on survival was caused by the number of solid nodules
252 but not GGNs. For GGN components, the IASLC guideline suggested that the prognosis of
253 multifocal GGNs is similar to single MIA or AIS [37], while others indicated that there are
254 metastatic GGNs on molecular level [38]. In our study, concurrent multiple GGNs in all three
255 stages did not increase HR, indicating that concurrent multiple GGNs in invasive lung cancer
256 possessed the same biological behavior as in multifocal GGN cases. For solid components, most
257 of the nodules were ≤ 6 mm and radiologically benign, with round shape, no spiculation, no
258 lobulation. But the growth of a few unresected nodules suggested their malignancy
259 (Supplementary Figure 5). It showed that the diagnosis using traditional radiological
260 characteristics for multiple PNs in stage III NSCLC patients is less reliable. The treatment failure
261 pattern analysis showed that higher TNN was related to distant metastasis (without statistical
262 significance due to small sample size) indicating that TNN was not only an indicator of IPM, but
263 also a visual representation of systematic tumor burden.

264 From a surgeon's perspective, the impact of PNs on surgical planning is dramatic. Convincing a
265 patient to accept unresected GGNs after surgery is difficult even if with the guideline's support. A
266 sublobar resection of a GGN may turn into lobectomy due to multiple GGNs detected by AI,
267 while lobectomy may also be altered into sublobar resection due to bilateral nodules clinically
268 diagnosed as separate primary lung cancer. However, no evidence showed the validity of such
269 approach. Our study provided the first proof of concept that TNN, driven by deep learning
270 algorithm, should be considered as a mandatory test before surgery planning. It would be
271 reasonable for surgeons to be more aggressive in resection of solid nodules instead of GGNs.
272 Moreover, neoadjuvant therapy should be considered for stage III patients with higher TNN for
273 better PN evaluation since empirical diagnosis may not be reliable.

274 Some may argue that PET-CT is a valid method in differentiating MPLC and IPM before
275 surgery, but the partial-volume effect of PET-CT prevented it from a proper diagnostic
276 performance for solid nodules less than 8mm, which represented 85.6% of the solid nodules in
277 our study [23, 39, 40]. Moreover, PET-CT is relatively expensive for most under-development
278 countries and is not affordable by every patient.

279 As a retrospective study, our results need validation before clinical application, however, no
280 public databases provide sufficient data, thus a prospective validation is needed and may be
281 time-consuming. The AI algorithm needs optimization to further reduce false positive rate, and
282 the performance in the detection of peri-vascular nodule still needs improvement. Currently, there
283 is a technological barrier in the alignment of pre- and post-operative PNs on chest CT. Given time,
284 we may be able to analyze the growth speed of PN and other information for better prognostic
285 modeling.

286 To our knowledge, this study is the first to identify that TNN measured by deep-learning
287 algorithm is an independent prognostic factor in stage III lung cancer. Our results suggested a
288 potentially critical clinical application of AI as a mandatory examination for surgery decision. The
289 current cut-off point of TNN is still preliminary but shows great potential and appeals to future
290 validation.

291 **CONFLICT OF INTEREST**

292 Author DW, JS, and WT were employed by the company Beijing Infervision Technology Co., Ltd.
293 The remaining authors declare that the research was conducted in the absence of any commercial
294 or financial relationships that could be construed as a potential conflict of interest.

295 **AUTHOR CONTRIBUTIONS**

296 XC took full responsibility for the content of the manuscript. QQ, and ZS had full access to all the
297 data in the study and took responsibility for the integrity of the data and the accuracy of the data
298 analysis. DW, JS, WT, XL, TL, NH, and FY contributed substantially to the study design, data
299 analysis and interpretation.

300 **FUNDING**

301 The authors received no specific funding for this work.

302 **ACKNOWLEDGEMENTS**

303 We would like to thank Yuqing Huang, Xianjun Min, and Guotian Pei from Beijing Haidian
304 Hospital for sharing their thoughts on this work.

305 REFERENCES

- 306 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of
307 incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
- 308 2. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. Reduced lung-cancer mortality with low-dose
309 computed tomographic screening. *N Engl J Med.* 2011;365(5):395-409.
- 310 3. Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd
311 ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest.* 2013;143(5 Suppl):e78S-e92S.
- 312 4. Ruparel M, Quaipe SL, Navani N, Wardle J, Janes SM, Baldwin DR. Pulmonary nodules and CT screening: the past, present and
313 future. *Thorax.* 2016;71(4):367-75.
- 314 5. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States,
315 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA Cancer J Clin.*
316 2017;67(2):100-21.
- 317 6. Wood DE, Kazerooni EA, Baum SL, Eapen GA, Ettinger DS, Hou L, et al. Lung Cancer Screening, Version 3.2018, NCCN
318 Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2018;16(4):412-41.
- 319 7. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer
320 Mortality with Volume CT Screening in a Randomized Trial. *N Engl J Med.* 2020;382(6):503-13.
- 321 8. Gould MK, Tang T, Liu IL, Lee J, Zheng C, Danforth KN, et al. Recent Trends in the Identification of Incidental Pulmonary
322 Nodules. *Am J Respir Crit Care Med.* 2015;192(10):1208-14.
- 323 9. Erickson BJ, Korfiatis P, Akkus Z, Kline TL. Machine Learning for Medical Imaging. *Radiographics.* 2017;37(2):505-15.
- 324 10. Armato SG, Altman MB, La Rivière PJ. Automated detection of lung nodules in CT scans: effect of image reconstruction
325 algorithm. *Med Phys.* 2003;30(3):461-72.
- 326 11. Hwang EJ, Park CM. Clinical Implementation of Deep Learning in Thoracic Radiology: Potential Applications and
327 Challenges. *Korean J Radiol.* 2020;21(5):511-25.
- 328 12. Ather S, Kadir T, Gleeson F. Artificial intelligence and radiomics in pulmonary nodule management: current status and
329 future applications. *Clin Radiol.* 2020;75(1):13-9.
- 330 13. Murphy A, Skalski M, Gaillard F. The utilisation of convolutional neural networks in detecting pulmonary nodules: a review.
331 *Br J Radiol.* 2018;91(1090):20180028.
- 332 14. Hua KL, Hsu CH, Hidayati SC, Cheng WH, Chen YJ. Computer-aided classification of lung nodules on computed
333 tomography images via deep learning technique. *Onco Targets Ther.* 2015;8:2015-22.
- 334 15. Cheng JZ, Ni D, Chou YH, Qin J, Tiu CM, Chang YC, et al. Computer-Aided Diagnosis with Deep Learning Architecture:
335 Applications to Breast Lesions in US Images and Pulmonary Nodules in CT Scans. *Sci Rep.* 2016;6:24454.
- 336 16. Li W, Cao P, Zhao D, Wang J. Pulmonary Nodule Classification with Deep Convolutional Neural Networks on Computed
337 Tomography Images. *Comput Math Methods Med.* 2016;2016:6215085.
- 338 17. Liu S, Xie Y, Jirapatnakul A, Reeves AP. Pulmonary nodule classification in lung cancer screening with three-dimensional
339 convolutional neural networks. *J Med Imaging (Bellingham).* 2017;4(4):041308.
- 340 18. da Silva GLF, Valente TLA, Silva AC, de Paiva AC, Gattass M. Convolutional neural network-based PSO for lung nodule
341 false positive reduction on CT images. *Comput Methods Programs Biomed.* 2018;162:109-18.
- 342 19. Xie Y, Xia Y, Zhang J, Song Y, Feng D, Fulham M, et al. Knowledge-based Collaborative Deep Learning for
343 Benign-Malignant Lung Nodule Classification on Chest CT. *IEEE Trans Med Imaging.* 2019;38(4):991-1004.
- 344 20. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules
345 detected on first screening CT. *N Engl J Med.* 2013;369(10):910-9.
- 346 21. Horeweg N, van Rosmalen J, Heuvelmans MA, van der Aalst CM, Vliegenthart R, Scholten ET, et al. Lung cancer
347 probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose

- 348 CT screening. *Lancet Oncol.* 2014;15(12):1332-41.
- 349 22. Walter JE, Heuvelmans MA, de Jong PA, Vliegenthart R, van Ooijen PMA, Peters RB, et al. Occurrence and lung cancer
350 probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled
351 NELSON trial. *Lancet Oncol.* 2016;17(7):907-16.
- 352 23. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, et al. Evaluation of individuals with pulmonary
353 nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians
354 evidence-based clinical practice guidelines. *Chest.* 2013;143(5 Suppl):e93S-e120S.
- 355 24. Callister ME, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, et al. British Thoracic Society guidelines for the
356 investigation and management of pulmonary nodules. *Thorax.* 2015;70 Suppl 2:ii1-ii54.
- 357 25. MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for Management of Incidental
358 Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. *Radiology.* 2017;284(1):228-43.
- 359 26. Heuvelmans MA, Walter JE, Peters RB, Bock GH, Yousaf-Khan U, Aalst CMV, et al. Relationship between nodule count
360 and lung cancer probability in baseline CT lung cancer screening: The NELSON study. *Lung Cancer.* 2017;113:45-50.
- 361 27. Walter JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, Groen HJM, van der Aalst CM, et al. Relationship between the
362 number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON
363 study. *Lung Cancer.* 2018;125:103-8.
- 364 28. Nair A, Screatton NJ, Holemans JA, Jones D, Clements L, Barton B, et al. The impact of trained radiographers as concurrent
365 readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial. *Eur*
366 *Radiol.* 2018;28(1):226-34.
- 367 29. Setio AA, Ciompi F, Litjens G, Gerke P, Jacobs C, van Riel SJ, et al. Pulmonary Nodule Detection in CT Images: False
368 Positive Reduction Using Multi-View Convolutional Networks. *IEEE Trans Med Imaging.* 2016;35(5):1160-9.
- 369 30. Dou Q, Chen H, Yu L, Qin J, Heng PA. Multilevel Contextual 3-D CNNs for False Positive Reduction in Pulmonary Nodule
370 Detection. *IEEE Trans Biomed Eng.* 2017;64(7):1558-67.
- 371 31. Tajbakhsh N, Suzuki K. Comparing two classes of end-to-end machine-learning models in lung nodule detection and
372 classification: MTANNs vs. CNNs. *Pattern Recognition.* 2017. p. 476-86.
- 373 32. Setio AAA, Traverso A, de Bel T, Berens MSN, Bogaard CVD, Cerello P, et al. Validation, comparison, and combination of
374 algorithms for automatic detection of pulmonary nodules in computed tomography images: The LUNA16 challenge. *Med Image*
375 *Anal.* 2017;42:1-13.
- 376 33. Wang Y, Yan F, Lu X, Zheng G, Zhang X, Wang C, et al. IILS: Intelligent imaging layout system for automatic imaging
377 report standardization and intra-interdisciplinary clinical workflow optimization. *EBioMedicine.* 2019;44:162-81.
- 378 34. Liu K, Li Q, Ma J, Zhou Z, Sun M, Deng Y, et al. Evaluating a Fully Automated Pulmonary Nodule Detection Approach and
379 Its Impact on Radiologist Performance. *Radiology: Artificial Intelligence.* 2019.
- 380 35. Yang F, Fan J, Tianzhou J, Yang F, Li Y, Liu X, et al. Population-based research of pulmonary subsolid nodule CT screening
381 and artificial intelligence application. *Chin J Thorac Cardiovasc Surg.* 2020.
- 382 36. Deterbeck FC, Nicholson AG, Franklin WA, Marom EM, Travis WD, Girard N, et al. The IASLC Lung Cancer Staging
383 Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of
384 Involvement in the Forthcoming Eighth Edition of the TNM Classification. *J Thorac Oncol.* 2016;11(5):639-50.
- 385 37. Deterbeck FC, Marom EM, Arenberg DA, Franklin WA, Nicholson AG, Travis WD, et al. The IASLC Lung Cancer Staging
386 Project: Background Data and Proposals for the Application of TNM Staging Rules to Lung Cancer Presenting as Multiple
387 Nodules with Ground Glass or Lepidic Features or a Pneumonic Type of Involvement in the Forthcoming Eighth Edition of the
388 TNM Classification. *J Thorac Oncol.* 2016;11(5):666-80.
- 389 38. Li R, Li X, Xue R, Yang F, Wang S, Li Y, et al. Early metastasis detected in patients with multifocal pulmonary ground-glass
390 opacities (GGOs). *Thorax.* 2018;73(3):290-2.
- 391 39. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. *J Nucl Med.* 2007;48(6):932-45.
- 392 40. Groheux D, Quere G, Blanc E, Lemarignier C, Vercellino L, de Margerie-Mellon C, et al. FDG PET-CT for solitary
393 pulmonary nodule and lung cancer: Literature review. *Diagn Interv Imaging.* 2016;97(10):1003-17.

394 **TABLES**

Table 1. Characteristics of the Patient Cohort (N = 2126)

Variables	Value
Age, y	
Median (IQR)	61 (54-68)
Sex	
Male	998 (46.9%)
Female	1128 (53.1%)
Smoking history	
No	1456 (68.5%)
Yes	670 (31.5%)
Comorbid	
No	850 (40.0%)
Yes	1276 (60.0%)
Surgical approach	
VATS	1997 (93.9%)
VATS converted to open	61 (2.9%)
Open	68 (3.2%)
Surgical procedure	
Sublobar resection	636 (29.9%)
Lobectomy	1419 (66.8%)
Sleeve lobectomy	39 (1.8%)
Pneumonectomy	32 (1.5%)
Histologic type	
Adenocarcinoma	1780 (83.7%)
Squamous Cell Carcinoma	280 (13.2%)
Others	66 (3.1%)
Pathologic T Stage	
T1	1383 (65.1%)
T2	579 (27.2%)
T3	115 (5.4%)
T4	49 (2.3%)
Pathologic N Stage	
N0	1765 (83.0%)
N1	145 (6.8%)
N2	216 (10.2%)
AJCC Stage (8th edition)	
IA1	499 (23.5%)
IA2	515 (24.2%)
IA3	265 (12.5%)
IB	347 (16.3%)
IIA	53 (2.5%)
IIB	184 (8.7%)
IIIA	213 (10.0%)
IIIB	50 (2.3%)
Complication	

No	2038 (95.9%)
Yes	88 (4.1%)
Adjuvant therapy	
No	1294 (60.9%)
Yes	445 (20.9%)
Unknown	387 (18.2%)

IQR, interquartile range; VATS, video-assisted thoracoscopic surgery.

395

Table 2. Characteristics of AI-Detected Pulmonary Nodules (n = 33410)

Features	Value
Total Nodule Number, per person	
Median (IQR)	12 (7-20)
Lobar Distribution	
Left Lower Lobe Nodule	6630 (19.9%)
Left Upper Lobe Nodule	7934 (23.7%)
Right Lower Lobe Nodule	6631 (19.9%)
Right Middle Lobe Nodule	2680 (8.0%)
Right Upper Lobe Nodule	9535 (28.5%)
Nodule Location	
Same-Lobe Nodule	9039 (27.0%)
Same-Side Nodule	9114 (27.3%)
Other-Side Nodule	15257 (45.7%)
Nodule Type	
Solid Nodule	17790 (53.2%)
Mixed Ground Glass Nodule	1616 (4.8%)
Pure Ground Glass Nodule	10276 (30.8%)
Calcific Nodule	2799 (8.4%)
Perifissural Nodule	929 (2.8%)
Solid Nodule Size	
≤ 6mm	13745 (77.2%)
> 6mm & ≤ 8mm	1487 (8.4%)
> 8mm	2558 (14.4%)
Mixed Ground Glass Nodule Size	
≤ 6mm	273 (16.9%)
> 6mm	1343 (83.1%)
Pure Ground Glass Nodule Size	
≤ 6mm	6675 (65.0%)
> 6mm	3601 (35.0%)

IQR, interquartile range.

396

Table 3. Univariate and Multivariate Analyses of Recurrence-Free Survival (RFS) Stratified by Stage

Variables	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	P Value	HR	95% CI	P Value
Stage I (n = 1626, event = 83)						
TNN (per 1 nodule increased)	1.010	0.998-1.022	0.102	1.007	0.994-1.020	0.292
Age (per 1 year increased)	1.034	1.012-1.057	0.002	1.016	0.994-1.039	0.156

Female Sex	0.650	0.422-0.999	0.050	1.088	0.613-1.933	0.773
Positive Smoking History	2.038	1.319-3.149	0.001	1.155	0.632-2.111	0.639
Comorbid Conditions	1.302	0.829-2.046	0.252			
Non-VATS Approach	3.280	1.483-7.256	0.003	1.814	0.805-4.087	0.151
Non-Sublobar Resection	1.861	1.087-3.186	0.024	1.027	0.585-1.803	0.926
Non-Adenocarcinoma	3.459	2.155-5.553	<0.001	2.217	1.271-3.866	0.005
Postoperative Complications	0.901	0.284-2.862	0.860			
Adjuvant Therapy	2.309	1.325-4.025	0.003	1.409	0.780-2.545	0.256
AJCC Stage IA2 (8th edition)	5.868	1.743-19.750	0.004	4.497	1.306-15.486	0.017
AJCC Stage IA3 (8th edition)	11.566	3.448-38.790	<0.001	7.719	2.202-27.065	0.001
AJCC Stage IB (8th edition)	13.864	4.272-44.990	<0.001	8.504	2.466-29.325	<0.001
Stage II (n = 237, event = 70)						
TNN (per 1 nodule increased)	1.000	0.988-1.013	0.973	1.001	0.987-1.015	0.880
Age (per 1 year increased)	1.031	1.004-1.058	0.022	1.030	1.002-1.059	0.034
Female Sex	1.504	0.924-2.449	0.100	1.588	0.966-2.611	0.068
Positive Smoking History	0.866	0.541-1.387	0.549			
Comorbid Conditions	1.545	0.941-2.536	0.085	1.274	0.758-2.139	0.361
Non-VATS Approach	1.393	0.820-2.367	0.220			
Non-Sublobar Resection	0.871	0.273-2.776	0.816			
Non-Adenocarcinoma	0.785	0.487-1.267	0.322			
Postoperative Complications	0.420	0.058-3.023	0.389			
Adjuvant Therapy	1.038	0.637-1.693	0.881			
AJCC Stage IIB (8th edition)	0.837	0.484-1.445	0.523			
Stage III (n = 263, event = 119)						
TNN (per 1 nodule increased)	1.015	1.005-1.024	0.003	1.012	1.002-1.022	0.021
Age (per 1 year increased)	1.022	1.004-1.041	0.019	1.019	1.000-1.039	0.051
Female Sex	1.062	0.734-1.535	0.751			
Positive Smoking History	1.013	0.707-1.452	0.942			
Comorbid Conditions	0.862	0.600-1.238	0.421			
Non-VATS Approach	1.574	1.029-2.407	0.036	1.700	1.105-2.614	0.016
Non-Sublobar Resection	0.835	0.367-1.902	0.668			
Non-Adenocarcinoma	0.958	0.646-1.422	0.832			
Postoperative Complications	1.425	0.718-2.828	0.311			
Adjuvant Therapy	0.694	0.467-1.031	0.070	0.812	0.539-1.224	0.319
AJCC Stage IIIB (8th edition)	1.421	0.912-2.215	0.121			

HR, hazard ratio; CI, confidence interval; TNN, total nodule number; VATS, video-assisted thoracoscopic surgery; AJCC, American Joint Committee on Cancer; Bold value, statistical significance.

397

Table 4. Univariate and Multivariate Analyses of Overall Survival (OS) Stratified by Stage

Variables	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	P Value	HR	95% CI	P Value
Stage I (n = 1626, event = 80)						
TNN (per 1 nodule increased)	1.003	0.989-1.017	0.689	0.995	0.978-1.012	0.572
Age (per 1 year increased)	1.080	1.054-1.106	<0.001	1.062	1.035-1.090	<0.001
Female Sex	0.381	0.241-0.603	<0.001	0.722	0.403-1.295	0.274
Positive Smoking History	2.634	1.697-4.090	<0.001	1.259	0.705-2.250	0.436


Comorbid Conditions	1.883	1.152-3.077	0.012	1.182	0.713-1.962	0.517
Non-VATS Approach	3.415	1.656-7.043	<0.001	2.163	1.028-4.553	0.042
Non-Sublobar Resection	1.232	0.737-2.059	0.427			
Non-Adenocarcinoma	3.921	2.472-6.220	<0.001	1.990	1.173-3.375	0.011
Postoperative Complications	1.155	0.418-3.191	0.782			
Adjuvant Therapy	1.044	0.531-2.052	0.900			
AJCC Stage IA2 (8th edition)	9.332	2.199-39.600	0.002	5.510	1.285-23.633	0.022
AJCC Stage IA3 (8th edition)	14.513	3.389-62.150	<0.001	6.554	1.494-28.743	0.013
AJCC Stage IB (8th edition)	14.918	3.575-62.240	<0.001	6.839	1.606-29.127	0.009
Stage II (n = 237, event = 61)						
TNN (per 1 nodule increased)	1.000	0.989-1.012	0.965	1.001	0.988-1.013	0.934
Age (per 1 year increased)	1.044	1.015-1.074	0.003	1.044	1.015-1.074	0.003
Female Sex	1.275	0.737-2.209	0.385			
Positive Smoking History	1.138	0.678-1.909	0.625			
Comorbid Conditions	1.394	0.831-2.339	0.208			
Non-VATS Approach	1.327	0.763-2.309	0.317			
Non-Sublobar Resection	0.601	0.187-1.929	0.392			
Non-Adenocarcinoma	1.105	0.668-1.827	0.699			
Postoperative Complications	0.496	0.069-3.587	0.488			
Adjuvant Therapy	0.723	0.436-1.201	0.210			
AJCC Stage IIB (8th edition)	0.700	0.395-1.240	0.222			
Stage III (n = 263, event = 108)						
TNN (per 1 nodule increased)	1.018	1.008-1.029	<0.001	1.013	1.002-1.025	0.021
Age (per 1 year increased)	1.035	1.015-1.056	<0.001	1.036	1.014-1.058	<0.001
Female Sex	0.645	0.428-0.972	0.036	1.054	0.568-1.955	0.868
Positive Smoking History	1.716	1.168-2.521	0.006	1.443	0.792-2.631	0.231
Comorbid Conditions	0.826	0.565-1.209	0.325			
Non-VATS Approach	2.340	1.556-3.517	<0.001	2.480	1.541-3.990	<0.001
Non-Sublobar Resection	0.724	0.293-1.789	0.483			
Non-Adenocarcinoma	1.614	1.093-2.384	0.016	0.933	0.567-1.535	0.784
Postoperative Complications	1.380	0.690-2.761	0.362			
Adjuvant Therapy	0.458	0.309-0.679	<0.001	0.560	0.394-0.913	0.017
AJCC Stage IIIB (8th edition)	1.841	1.176-2.882	0.008	1.338	0.823-2.175	0.241

HR, hazard ratio; CI, confidence interval; TNN, total nodule number; VATS, video-assisted thoracoscopic surgery; AJCC, American Joint Committee on Cancer; Bold value, statistical significance.

398

399


400 **FIGURE CAPTIONS**



401

402 **Figure 1. The framework of deep learning powered pulmonary nodule detection algorithm**
403 **and an example of 3D reconstruction of AI-detected nodules with corresponding CT images**
404 **under the lung window setting.** (A) Feature maps are extracted using CNN. A RPN is used to
405 obtain potential regions from extracted features. After ROI pooling and fully-connected layers,
406 nodules are detected with rectangular proposals. (B) Seven nodules are detected by AI algorithm,
407 including 1 solid nodule (#5), 2 mixed GGNs (#4, #7), and 4 pure GGNs (#1, #2, #3, #6). RPN,
408 regional proposal network; ROI, region of interest; TNN, total nodule number; CNN,
409 convolutional neural network; GGN, ground-glass nodule.


410



411

412 **Figure 2. Frequency distribution of AI-detected nodules.** (A) TNN, (B) solid nodule number,
413 (C) subsolid nodule number, (D) TNN stratified by pathological stage, (E) solid nodule number
414 stratified by pathological stage, (F) subsolid nodule number stratified by pathological stage. TNN,
415 total nodule number; IQR, interquartile range; ANOVA, analysis of variance.

416




417

418 **Figure 3. Kaplan-Meier curves showing survival by stage in entire cohort. (A)**

419 recurrence-free survival, (B) overall survival. Comparisons were conducted using log-rank test.


420



421

422 **Figure 4. Kaplan-Meier curves showing overall survival by AI-detected nodule number in**
 423 **stage III cohort.** (A) TNN, (B) upper-lobe nodule number, (C) same-side nodule number, (D)
 424 other-side nodule number, (E) solid nodule number, (F) small ($\leq 6\text{mm}$) solid nodule number.
 425 Comparisons were conducted using log-rank test. TNN, total nodule number.

426



427

428 **Figure 5. Survival tree analysis.** (A) Recursive partitioning-generated survival tree based on the
 429 best split of overall survival using AI-detected TNN and the 8th edition of AJCC stage. Both TNN
 430 and stage were modeled as categorical variables. (B) Kaplan-Meier curves showing overall
 431 survival by tree-based scheme in entire cohort. Comparisons were conducted using log-rank test.
 432 AJCC, American Joint Committee on Cancer; TNN, total nodule number.